Extravasation: a dreaded complication of chemotherapy.

Department of Medical Oncology, AZ Middelheim, Antwerp, Belgium.
Annals of Oncology (Impact Factor: 6.58). 02/2003; 14 Suppl 3:iii26-30. DOI: 10.1093/annonc/mdg744
Source: PubMed
1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To review the literature regarding the incidence, current practice, guideline recommendations, nursing management, and knowledge gaps relevant to vesicant extravasation. Published research articles, books, case reports, and national guidelines. Vesicant extravasation is a relatively rare but significant complication of chemotherapy administration. Extravasation may have a range of consequences that can cause serious physical and quality-of-life effects. Knowledge of risk factors and preventive measures can reduce patient risk. Data-based and empirical management strategies such as immediate local measures (agent withdrawal, comfort measures, and medical interventions) may minimize risk for extravasation, as well as lead to timely recognition and management and decreased morbidity should extravasation occur. Vesicant extravasation and sequelae constitute a complex patient problem that clinicians should strive to prevent or to minimize injury should it occur. To this end, clinicians must demonstrate awareness of risks and use specialized knowledge while administering vesicant agents. Only nurses knowledgeable about extravasation and skilled in associated techniques should assume responsibility for vesicant administration.
    Oncology Nursing Forum 12/2006; 33(6):1134-41. DOI:10.1188/06.ONF.1134-1141 · 1.91 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A patient with metastatic ovarian cancer was treated with liposomal doxorubicin and carboplatin. She had an extravasation during liposomal doxorubicin infusion. Initially, she was treated conservatively with cold compresses and topical treatment. However, because of worsening of symptoms, she received dexrazoxane once daily for 3 days after which complete recovery occurred. This is the first casereport on symptomatic extravasation of liposomal doxorubicin treated with dexrazoxane.
    Anti-cancer drugs 09/2011; 23(1):139-40. DOI:10.1097/CAD.0b013e32834be51a · 1.89 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: IntroductionPeritoneal carcinomatosis frequently signals terminal stage in many cancers of gastrointestinal and gynaecological origins. Cytoreductive surgery (CRS) and intraperitoneal hyperthermic chemotherapy (HIPEC) was first popularised in the early 1990s and has become the mainstay of treatment for selected patients with peritoneal carcinomatoses, especially in pseudomyxoma peritonei, significantly improving overall survival rates [1-3]. Cytoreductive surgery removes all visible tumour tissue, while intraperitoneal administration of chemotherapeutic agents targets microscopic disease. The major benefit of HIPEC is regional dose intensity whilst limiting systemic absorption. Hyperthermia produces “heat shock” proteins and is in itself cytotoxic at cell and tissue levels. Additionally, studies have also shown that heat improves the penetration of the chemotherapy drug and enhances the cytotoxicity of some drugs [4].Postoperative morbidity related to this procedure has been acknowledg ...
    Journal of Gastrointestinal Cancer 11/2014; 46(1). DOI:10.1007/s12029-014-9665-0